NASDAQ:MGNX - MacroGenics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$21.60 -0.33 (-1.50 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$21.93
Today's Range$21.34 - $22.26
52-Week Range$14.36 - $32.74
Volume156,800 shs
Average Volume335,044 shs
Market Capitalization$925.49 million
P/E Ratio-39.94
Dividend YieldN/A
Beta2.46
MacroGenics logoMacroGenics, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases in the United States. The company's advanced clinical product candidate is Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets human epidermal growth factor receptor 2-expressing tumors, such as various breast and gastroesophageal cancers. It is also developing Flotetuzumab, a DART molecule that targets CD123 and CD3; MGA012, a monoclonal antibody, which targets programmed cell death protein 1 (PD-1); MGD013, a DART molecule that enables the co-blockade with a single recombinant agent of two immune checkpoint molecules; MGD019, a preclinical DART molecule designed to recognize the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company develops MGD009, a DART molecule recognizes B7-H3 and CD3; MGC018, a B7-H3 antibody-drug conjugate; MGD007, a DART molecule, which targets glycoprotein A33 and CD3; Teplizumab, an anti-CD3 monoclonal antibody to treat type 1 diabetes; MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; and MGD014, a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells and CD3-expressing T cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

Receive MGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MGNX
CUSIPN/A
Phone301-251-5172

Debt

Debt-to-Equity RatioN/A
Current Ratio5.43
Quick Ratio5.43

Price-To-Earnings

Trailing P/E Ratio-39.94
Forward P/E Ratio-4.56
P/E GrowthN/A

Sales & Book Value

Annual Sales$157.74 million
Price / Sales5.78
Cash FlowN/A
Price / CashN/A
Book Value$8.13 per share
Price / Book2.66

Profitability

EPS (Most Recent Fiscal Year)($0.54)
Net Income$-19,620,000.00
Net Margins-19.64%
Return on Equity-13.03%
Return on Assets-10.36%

Miscellaneous

Employees330
Outstanding Shares42,200,000
Market Cap$925.49

The Truth About Cryptocurrencies

MacroGenics (NASDAQ:MGNX) Frequently Asked Questions

What is MacroGenics' stock symbol?

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

How were MacroGenics' earnings last quarter?

MacroGenics Inc (NASDAQ:MGNX) released its quarterly earnings data on Monday, May, 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.08) by $0.26. The biopharmaceutical company had revenue of $4.70 million for the quarter, compared to the consensus estimate of $7.46 million. MacroGenics had a negative net margin of 19.64% and a negative return on equity of 13.03%. View MacroGenics' Earnings History.

What price target have analysts set for MGNX?

11 brokers have issued 12-month price targets for MacroGenics' stock. Their forecasts range from $22.00 to $44.00. On average, they anticipate MacroGenics' stock price to reach $31.50 in the next year. This suggests a possible upside of 45.8% from the stock's current price. View Analyst Ratings for MacroGenics.

What is the consensus analysts' recommendation for MacroGenics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about MacroGenics stock?

Here are some recent quotes from research analysts about MacroGenics stock:
  • 1. HC Wainwright analysts commented, "We are currently not valuing the B7-H3 franchise pending clinical updates on the combination program with Keytruda and preliminary read from the B7-H3 x CD3 DART molecule, which if positive could rival the remainder of the pipeline in terms of clinical importance. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial." (6/4/2018)
  • 2. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (5/9/2018)

Who are some of MacroGenics' key competitors?

Who are MacroGenics' key executives?

MacroGenics' management team includes the folowing people:
  • Dr. Scott Koenig, CEO, Pres & Director (Age 66)
  • Mr. James Karrels, Sr. VP, CFO & Sec. (Age 51)
  • Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 64)
  • Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 45)
  • Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 56)

Has MacroGenics been receiving favorable news coverage?

Media stories about MGNX stock have been trending somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. MacroGenics earned a news impact score of 0.11 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.46 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of MacroGenics?

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MacroGenics' stock price today?

One share of MGNX stock can currently be purchased for approximately $21.60.

How big of a company is MacroGenics?

MacroGenics has a market capitalization of $925.49 million and generates $157.74 million in revenue each year. The biopharmaceutical company earns $-19,620,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. MacroGenics employs 330 workers across the globe.

How can I contact MacroGenics?

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.


MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  449
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Featured Article: Relative Strength Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.